Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Colchicine Patent Expiration

Colchicine is Used for treating and reducing the risk of cardiovascular events, acute myocardial infarction, atherosclerotic vascular disease, and inflammation. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Colcrys on Jul 29, 2009. Other drugs containing Colchicine are Gloperba, Lodoco, Mitigare. 18 different companies have introduced drugs containing Colchicine.


Colchicine Patents

Given below is the list of patents protecting Colchicine, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Country : United States (US)
Patent Category : All
Dosage Form Category : Others
NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Gloperba US10226423 Colchicine drug-to-drug interactions Dec 20, 2037 Scilex Pharms
Gloperba US10383820 Colchicine drug-to-drug interactions Nov 22, 2036 Scilex Pharms
Gloperba US10383821 Colchicine drug-to-drug interactions Nov 22, 2036 Scilex Pharms
Gloperba US12274751 Composition and method of the use of colchicine oral liquid Nov 22, 2036 Scilex Pharms
Gloperba US12514819 Colchicine Drug-To-Drug Interactions Nov 22, 2036 Scilex Pharms
Gloperba US9907751 Composition and method of use of colchicine oral liquid Nov 22, 2036 Scilex Pharms
Lodoco US10130585 Methods of treating and/or preventing cardiovascular disease May 09, 2034 Agepha Pharma Fz
Lodoco US10206891 Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent Nov 01, 2033 Agepha Pharma Fz
Lodoco US10265281 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US10842762 Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent Nov 01, 2033 Agepha Pharma Fz
Lodoco US11026899 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US11026900 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US11026901 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US11944594 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US11944595 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US12233035 Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin Nov 01, 2033 Agepha Pharma Fz
Lodoco US12280025 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US12364675 Treatment Or Prevention Of Cardiovascular Events Via The Administration Of A Colchicine Derivative Nov 01, 2033 Agepha Pharma Fz
Lodoco US9744144 Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent Nov 01, 2033 Agepha Pharma Fz
Mitigare US8927607 Methods of colchicine administration Aug 22, 2033 Hikma Intl Pharms
Mitigare US9399036 Methods of colchicine administration Aug 22, 2033 Hikma Intl Pharms
Mitigare US9555029 Methods of colchicine administration Aug 22, 2033 Hikma Intl Pharms
Mitigare US9675613 Methods of colchicine administration Aug 22, 2033 Hikma Intl Pharms
Mitigare US9789108 Methods of colchicine administration Aug 22, 2033 Hikma Intl Pharms
Colcrys US7820681 Methods for concomitant administration of colchicine and a second active agent Feb 17, 2029 Takeda Pharms Usa
Colcrys US7906519 Methods for concomitant administration of colchicine and a second active agent Feb 17, 2029 Takeda Pharms Usa
Colcrys US7915269 Methods for concomitant administration of colchicine and a second active agent Feb 17, 2029 Takeda Pharms Usa
Colcrys US8440721 Methods for concomitant administration of colchicine and a second active agent Feb 17, 2029 Takeda Pharms Usa
Colcrys US8440722 Methods for concomitant administration of colchicine and a second active agent Feb 17, 2029 Takeda Pharms Usa
Colcrys US7601758 Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares Feb 10, 2029 Takeda Pharms Usa
Colcrys US7619004 Methods for concomitant administration of colchicine and macrolide antibiotics Dec 03, 2028 Takeda Pharms Usa
Colcrys US7935731 Methods for concomitant administration of colchicine and macrolide antibiotics Dec 03, 2028 Takeda Pharms Usa
Colcrys US7964647 Colchicine compositions and methods Oct 06, 2028 Takeda Pharms Usa
Colcrys US7964648 Methods for concomitant administration of colchicine and a second active agent Oct 06, 2028 Takeda Pharms Usa
Colcrys US7981938 Colchicine compositions and methods Oct 06, 2028 Takeda Pharms Usa
Colcrys US8093296 Methods for concomitant administration of colchicine and macrolide antibiotics Oct 06, 2028 Takeda Pharms Usa
Colcrys US8093297 Methods for concomitant administration of colchicine and a second active agent Oct 06, 2028 Takeda Pharms Usa
Colcrys US8093298 Methods for concomitant administration of colchicine and macrolide antibiotics Oct 06, 2028 Takeda Pharms Usa
Colcrys US8097655 Methods for concomitant administration of colchicine and macrolide antibiotics Oct 06, 2028 Takeda Pharms Usa
Colcrys US8415395 Colchicine compositions and methods Oct 06, 2028 Takeda Pharms Usa
Colcrys US8415396 Colchine compositions and methods Oct 06, 2028 Takeda Pharms Usa



Colchicine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Clinical Trials

Recent Clinical Trials on Colchicine:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Colchicine Effect on Amyotrophic Lateral Sclerosis Patients Azienda Ospedaliero-Universitaria di Modena NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
Colchicine and Inflammation in Aortic Stenosis Radboud University Medical Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage Population Health Research Institute NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Tan Tock Seng Hospital NA RECRUITING
(Aug 1, 2026)
PHASE2
Colchicine Use in Intracranial Atherosclerotic Disease Chinese University of Hong Kong NA RECRUITING
(Jul 1, 2026)
PHASE2
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes Asger Lund, MD NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) Hamilton Health Sciences Corporation NA COMPLETED
(Jul 1, 2026)
PHASE2
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) Ottawa Hospital Research Institute NA RECRUITING
(Jul 1, 2026)
PHASE3
The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL The George Institute NA RECRUITING
(Jul 1, 2026)
PHASE3
Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment Brigham and Women's Hospital NA RECRUITING
(Jul 1, 2026)
PHASE2
PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis Duke University NA RECRUITING
(Jul 1, 2026)
PHASE3
Colchicine in Chronic Limb-Threatening Ischemia Shin Kong Wu Ho-Su Memorial Hospital NA RECRUITING
(Jul 1, 2026)
PHASE3
Colchicine for Autoimmune and Subacute Thyroiditis Mansoura University NA RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial National Taiwan University Hospital NA ENROLLING BY INVITATION
(Jul 1, 2026)
PHASE2, PHASE3
Colchicine to Reduce Coronary Artery Inflammation in People With HIV Instituto de Investigación Hospital Universitario La Paz NA RECRUITING
(Jul 1, 2026)
PHASE2
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2
RegoNivo vs Standard of Care Chemotherapy in AGOC Australasian Gastro-Intestinal Trials Group NA COMPLETED
(Jun 1, 2026)
PHASE3
Transition to KPL-387 Monotherapy Dosing & Administration Study Kiniksa Pharmaceuticals International, plc NA RECRUITING
(Jun 1, 2026)
PHASE2
Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD University of Texas Southwestern Medical Center NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2
Study to Evaluate the Safety of Colchicine Rutgers, The State University of New Jersey NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1
Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis Lille Catholic University NA COMPLETED
(Apr 1, 2026)
PHASE3
Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine Ottawa Heart Institute Research Corporation NA COMPLETED
(Apr 1, 2026)
PHASE3
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine Niguarda Hospital NA RECRUITING
(Apr 1, 2026)
PHASE3
Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study Virginia Commonwealth University NA RECRUITING
(Apr 1, 2026)
PHASE1
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk Population Health Research Institute NA RECRUITING
(Mar 1, 2026)
PHASE3


Colchicine Generic API Manufacturers

Several generic applications have been filed for Colchicine. The first generic version for Colchicine was by Amneal Pharmaceuticals and was approved on Sep 28, 2016. And the latest generic version is by Micro Labs Ltd and was approved on Feb 17, 2026.

Given below is the list of companies who have filed for Colchicine generic, along with the locations of their manufacturing plants worldwide.